Study of ibuzatrelvir for immunocompromised adults with COVID-19
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests an investigational medicine called ibuzatrelvir for adults with COVID-19 who have a weakened immune system. The study aims to see if it helps them recover and avoid severe illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have tested positive for COVID-19 and have symptoms that started within the last 5 days.
- Your COVID-19 symptoms are mild or moderate (not severe), and you do not need extra oxygen.
- You have a severely weakened immune system due to certain conditions or treatments, such as an organ transplant or recent cancer treatment.
- You are not currently on dialysis for kidney failure.
- You are not pregnant or breastfeeding.
- You have not taken other antiviral medications for this COVID-19 infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called clazakizumab, which may reduce harmful inflammation in the lungs of people hospitalized with COVID-19. It aims to see if the drug can help patients recover better than a placebo.
This trial tests if a new medicine called ibuzatrelvir can help people with COVID-19 who have certain health risks avoid severe illness. It is for patients who cannot or choose not to take another COVID-19 pill called Paxlovid.
This trial studies a longer course of remdesivir combined with nirmatrelvir/ritonavir (Paxlovid) for immunocompromised patients who have persistent COVID-19. The goal is to see if this combination helps clear the virus better.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.
This study tests an experimental oral antiviral, secutrelvir, for people with mild to moderate COVID-19 who are not sick enough to need hospital care. The medicine aims to reduce symptoms and help you recover faster.
Hear when a new COVID-19 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.